CRIS100

Phase 1Small molecule

CCristália Produtos Químicos Farmacêuticos Ltda.

CRIS100 is one of 49 small molecule programs targeting Spinal Cord Injury. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Cord InjuryNot yet recruiting

Spinal Cord InjuryPhase 1

Not yet recruiting

Competition

Competitive Landscape

65 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

5 2

Keppra

UCB

Approved

1 3

Cialis

Eli Lilly

Approved

1 4

Lioresal

Calciferol

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 7

Prolia

OOrganon and Co

Approved

2 8

Xarelto

WWim Janssens

Approved

1 9

Botox

RRevance Therapeutics, Inc.

Approved

1 10

Spiriva

Boehringer Ingelheim

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Spinal Cord Injury

NCT05739734

Clinical

Trials by Indication[1]

Spinal Cord Injury1 trial

Safety of CRIS100 on Treatment Spinal Cord Injury

Not yet recruiting·CCristália Produtos Químicos Farmacêuticos Ltda.·Phase 1·NCT05739734·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CRIS100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CRIS100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CRIS100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cristália Produtos Químicos Farmacêuticos Ltda. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCristália Produtos Químicos Farmacêuticos Ltda.

CRIS100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News